De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sprint Bioscience Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Johan Emilsson

Algemeen directeur

SEK 1.7m

Totale compensatie

Percentage CEO-salaris	25.0%
Dienstverband CEO	less than a year
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Jun 12

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Feb 19

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Nov 19

Analyse CEO-vergoeding

Hoe is Johan Emilsson's beloning veranderd ten opzichte van Sprint Bioscience's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	SEK 15m
Mar 31 2024	n/a	n/a	SEK 9m
Dec 31 2023	SEK 2m	SEK 420k	-SEK 438k

Compensatie versus markt: De totale vergoeding ($USD 163.62K ) Johan } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 253.61K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Johan te vergelijken met de prestaties van het bedrijf.

CEO

Johan Emilsson (40 yo)

less than a year

Tenure

SEK 1,680,000

Compensatie

Mr. Johan Emilsson is Chief Executive Officer of Sprint Bioscience AB (publ) since October 01, 2023. He has broad experience in business development within the pharmaceutical industry and most recently fro...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Johan Emilsson	Chief Executive Officer	less than a year	SEK 1.68m	0.029% SEK 27.8k
Pär Nordlund	Founder	no data	SEK 25.00k	0.91% SEK 885.7k
Martin Andersson	Co-Founder & Chief Scientific Officer	15.8yrs	geen gegevens	0.39% SEK 380.0k
Kenth Hallberg	Founder & Director of Structural Chemistry	no data	geen gegevens	geen gegevens
Mathias Skalmstad	Chief Financial Officer	3.2yrs	geen gegevens	0.10% SEK 99.9k
Anne-Marie Wenthzel	Chief Business Officer	no data	geen gegevens	0.26% SEK 254.1k

3.2yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SPRINT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Svein Mathisen	Independent Director	4.8yrs	SEK 150.00k	0.064% SEK 62.5k
Bjorn Sjostrand	Independent Chairman of the Board	3.8yrs	SEK 300.00k	1.26% SEK 1.2m
Lewis Cantley	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Rune Nordlander	Director	14.8yrs	SEK 150.00k	15.13% SEK 14.7m
Fredrik Lehmann	Independent Director	5.4yrs	SEK 150.00k	0.072% SEK 69.4k
Robert Devita	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gunilla Enblad	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Karen From	Independent Director	1.4yrs	SEK 88.00k	geen gegevens

4.8yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SPRINT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Sprint Bioscience Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

Director recently bought kr336k worth of stock

Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte Leife

Recent updates

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)

Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)

Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Now 23% undervalued after recent price drop

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)

Price target decreased to kr3.30

Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)

Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)

First quarter 2022 earnings: EPS misses analyst expectations

Sprint Bioscience Launches NIMA at BIO International

Forecast to breakeven in 2023

High number of new and inexperienced directors

Full year 2021 earnings: EPS misses analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations

Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)

Director recently bought kr336k worth of stock

Sprint Bioscience AB (publ) Adds New Cancer Drug Program to its Project Portfolio

Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)

Sprint Bioscience AB (publ) announced that it has received SEK 20.713701 million in funding

Interim Chief Executive Officer Charlotte Leife has left the company

Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte Leife

Revenue and earnings beat expectations

New 90-day low: kr6.52

Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)

New 90-day low: kr7.10

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Third quarter 2020 earnings released: kr0.36 loss per share

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd